Decision on the commencement of review of available strategic options
Current report no 34/2018
Legal basis: Article 17(1) of MAR – inside information.
The Management Board of Medicalgorithmics S.A. (“Company”, “Issuer”) informs that on 1 October 2018 it decided to commence a review of strategic options supporting further development of the Issuer’s capital group (“Group”) available to the Company.
The review of strategic options will enable identification of possible development directions of the Group’s operations, resulting in the selection of the preferred measures to achieve the Group’s long-term goal, which is to ensure the best possible position for the Group on the market for advanced systems for cardiology and to maximize value for the Company’s shareholders.
The Management Board of the Company will carry out an analysis of different strategic options in all areas of the Group’s business operations; it will also consider obtaining a strategic or financial investor, entering into a strategic alliance, performing an otherwise-structured transaction as well as none of the listed measures.
The Management Board of the Company will commence selection of consultants that will support the Company in the strategic options review process. The communication consultant of the Company in the area of the strategic options review is CC Group Sp. z o.o., with Adam Kalkusiński, President of the Management Board as a contact person, e-mail address: firstname.lastname@example.org.
At the same time the Management Board of the Company informs that to date it did not make any decision concerning the selection of a specific strategic option and allows for the possibility that no strategic option will be selected. The Issuer shall publicly announce information on the course of the review process in line with applicable regulations.